Neurology/psychiatricBrain-penetrant NLRP3 inhibitor shows promise in Parkinson’sResearchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain penetration designed for the treatment of Parkinson’s disease.